MRI studies have revealed that moderate and late preterm babies—born 32 to 36 weeks into gestation—have similar brain abnormalities as those of very preterm infants born prior to 32 weeks of gestation.

18F-DTBZ PET is a potential imaging biomarker for measuring dopaminergic degeneration in vivo and monitoring Parkinson disease (PD) severity, according to a study published by JAMA Neurology on June 9. 

A smaller hippocampal volume, which is the area of the brain important for memory, was observed in a group of collegiate football players who had experienced a concussion and was also associated with length of football experience, according to a study published on May 13 by JAMA.

Brain injuries affect roughly three in 1,000 U.S. babies born full-term. A report from the American College of Obstetricians and Gynecologists and the American Academy of Pediatrics is helping to identify when these injuries occurred.

Characteristics of the brain’s resting-state functional architecture are pertinent to understanding the relationship between the neural substrate and executive function in young patients with attention deficit hyperactivity disorder (ADHD), according to a study published on April 30 by Radiology. 

The duration and severity of type 2 diabetes may be associated with brain degeneration, according to a study published online April 29 by Radiology. Contrary to common belief, the research also found that diabetes may not be directly associated with small vessel ischemic disease (SVID).

Those who have more years of education could recover better from a traumatic brain injury (TBI), according to a study published online April 23 by Neurology.

This week, the FDA approved the use of F-18 florbetaben (Neuraceq) as a diagnostic amyloid agent to help rule out Alzheimer’s disease (AD). The approval of Neuraceq came a day after the Alzheimer’s Association released its 2014 Alzheimer’s Disease Facts and Figures report, which only underscored the urgency of improving AD diagnostic tools and treatments.